Suppr超能文献

目前在肾移植中使用抗胸腺球蛋白作为诱导治疗方案:综述。

Current use of antithymoglobulin as induction regimen in kidney transplantation: A review.

机构信息

Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea.

Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea.

出版信息

Medicine (Baltimore). 2024 Mar 1;103(9):e37242. doi: 10.1097/MD.0000000000037242.

Abstract

Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future.

摘要

目前,器官移植中使用了各种免疫抑制剂。特别是,抗胸腺球蛋白是韩国肾移植中广泛使用的药物,占所有诱导治疗的 20%。根据现有研究,抗胸腺球蛋白诱导治疗与其他免疫疗法相比,根据肾移植情况(已故供体、活体供体、低危受者和高危受者)或抗胸腺球蛋白剂量,具有一些优缺点。在这篇综述中,我们总结了迄今为止对抗胸腺球蛋白的研究,希望未来能积极开展肾移植对抗胸腺球蛋白的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8874/10906612/1249335a6ab7/medi-103-e37242-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验